Literature DB >> 26867494

Novel pre-mRNA splicing of intronically integrated HBV generates oncogenic chimera in hepatocellular carcinoma.

Yung-Tuen Chiu1, John K L Wong2, Shing-Wan Choi2, Karen M F Sze1, Daniel W H Ho1, Lo-Kong Chan1, Joyce M F Lee1, Kwan Man3, Stacey Cherny2, Wan-Ling Yang4, Chun-Ming Wong5, Pak-Chung Sham6, Irene O L Ng7.   

Abstract

BACKGROUND & AIMS: Hepatitis B virus (HBV) integration is common in HBV-associated hepatocellular carcinoma (HCC) and may play an important pathogenic role through the production of chimeric HBV-human transcripts. We aimed to screen the transcriptome for HBV integrations in HCCs.
METHODS: Transcriptome sequencing was performed on paired HBV-associated HCCs and corresponding non-tumorous liver tissues to identify viral-human chimeric sites. Validation was further performed in an expanded cohort of human HCCs.
RESULTS: Here we report the discovery of a novel pre-mRNA splicing mechanism in generating HBV-human chimeric protein. This mechanism was exemplified by the formation of a recurrent HBV-cyclin A2 (CCNA2) chimeric transcript (A2S), as detected in 12.5% (6 of 48) of HCC patients, but in none of the 22 non-HCC HBV-associated cirrhotic liver samples examined. Upon the integration of HBV into the intron of the CCNA2 gene, the mammalian splicing machinery utilized the foreign splice sites at 282nt. and 458nt. of the HBV genome to generate a pseudo-exon, forming an in-frame chimeric fusion with CCNA2. The A2S chimeric protein gained a non-degradable property and promoted cell cycle progression, demonstrating its potential oncogenic functions.
CONCLUSIONS: A pre-mRNA splicing mechanism is involved in the formation of HBV-human chimeric proteins. This represents a novel and possibly common mechanism underlying the formation of HBV-human chimeric transcripts from intronically integrated HBV genome with functional impact. LAY
SUMMARY: HBV is involved in the mammalian pre-mRNA splicing machinery in the generation of potential tumorigenic HBV-human chimeras. This study also provided insight on the impact of intronic HBV integration with the gain of splice sites in the development of HBV-associated HCC.
Copyright © 2016 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Cyclin A2; HBV integration; Hepatocellular carcinoma; Splicing

Mesh:

Substances:

Year:  2016        PMID: 26867494     DOI: 10.1016/j.jhep.2016.02.005

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  13 in total

Review 1.  Non-coding RNAs in hepatocellular carcinoma: molecular functions and pathological implications.

Authors:  Chun-Ming Wong; Felice Ho-Ching Tsang; Irene Oi-Lin Ng
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2018-01-10       Impact factor: 46.802

2.  Hepatitis B Virus Integration into Transcriptionally Active Loci and HBV-Associated Hepatocellular Carcinoma.

Authors:  Maria Bousali; Timokratis Karamitros
Journal:  Microorganisms       Date:  2022-01-24

Review 3.  Hepatitis B virus pathogenesis: Fresh insights into hepatitis B virus RNA.

Authors:  Kazuma Sekiba; Motoyuki Otsuka; Motoko Ohno; Mari Yamagami; Takahiro Kishikawa; Tatsunori Suzuki; Rei Ishibashi; Takahiro Seimiya; Eri Tanaka; Kazuhiko Koike
Journal:  World J Gastroenterol       Date:  2018-06-07       Impact factor: 5.742

4.  Nucleotide variants in hepatitis B virus preS region predict the recurrence of hepatocellular carcinoma.

Authors:  Xi Chen; Minfeng Zhang; Nan Li; Rui Pu; Ting Wu; Yibo Ding; Peng Cai; Hongwei Zhang; Jun Zhao; Jianhua Yin; Guangwen Cao
Journal:  Aging (Albany NY)       Date:  2021-09-17       Impact factor: 5.682

5.  Immunological alterations after immunotherapy with short lived HBV-TCR T cells associates with long-term treatment response in HBV-HCC.

Authors:  Anthony Tanoto Tan; Fanping Meng; Jiehua Jin; Ji-Yuan Zhang; Si-Yu Wang; Lei Shi; Ming Shi; Yuanyuan Li; Yunbo Xie; Li-Min Liu; Chun-Bao Zhou; Alicia Chua; Zi Zong Ho; Junqing Luan; Jinfang Zhao; Jing Li; Lu-En Wai; Sarene Koh; Tingting Wang; Antonio Bertoletti; Fu-Sheng Wang
Journal:  Hepatol Commun       Date:  2021-12-21

6.  Single-cell RNA sequencing shows the immunosuppressive landscape and tumor heterogeneity of HBV-associated hepatocellular carcinoma.

Authors:  Daniel Wai-Hung Ho; Yu-Man Tsui; Lo-Kong Chan; Karen Man-Fong Sze; Xin Zhang; Jacinth Wing-Sum Cheu; Yung-Tuen Chiu; Joyce Man-Fong Lee; Albert Chi-Yan Chan; Elaine Tin-Yan Cheung; Derek Tsz-Wai Yau; Nam-Hung Chia; Irene Lai-Oi Lo; Pak-Chung Sham; Tan-To Cheung; Carmen Chak-Lui Wong; Irene Oi-Lin Ng
Journal:  Nat Commun       Date:  2021-06-17       Impact factor: 14.919

Review 7.  Neoantigen vaccine: An emerging immunotherapy for hepatocellular carcinoma.

Authors:  Pu Chen; Qiong-Xuan Fang; Dong-Bo Chen; Hong-Song Chen
Journal:  World J Gastrointest Oncol       Date:  2021-07-15

8.  A pilot systematic genomic comparison of recurrence risks of hepatitis B virus-associated hepatocellular carcinoma with low- and high-degree liver fibrosis.

Authors:  Seungyeul Yoo; Wenhui Wang; Qin Wang; M Isabel Fiel; Eunjee Lee; Spiros P Hiotis; Jun Zhu
Journal:  BMC Med       Date:  2017-12-07       Impact factor: 8.775

9.  Bioinformatics analysis reveals meaningful markers and outcome predictors in HBV-associated hepatocellular carcinoma.

Authors:  Lijie Zhang; Joyman Makamure; Dan Zhao; Yiming Liu; Xiaopeng Guo; Chuansheng Zheng; Bin Liang
Journal:  Exp Ther Med       Date:  2020-05-06       Impact factor: 2.447

Review 10.  Clinical Implications of Hepatitis B Virus RNA and Covalently Closed Circular DNA in Monitoring Patients with Chronic Hepatitis B Today with a Gaze into the Future: The Field Is Unprepared for a Sterilizing Cure.

Authors:  Anastasiya Kostyusheva; Dmitry Kostyushev; Sergey Brezgin; Elena Volchkova; Vladimir Chulanov
Journal:  Genes (Basel)       Date:  2018-10-05       Impact factor: 4.096

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.